The combination of durvalumab and tremelimumab-actl conferred a sustained OS benefit at 4 years among patients with unresectable hepatocellular carcinoma, according to phase 3 trial results from the ...

Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) ...

The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population. The trial showed the combination significantly ...

Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally ...

Please provide your email address to receive an email when new articles are posted on . Trifluridine-tipiracil plus bevacizumab was not superior to capecitabine plus bevacizumab but presented no new ...

Nivolumab in patients (pts) with advanced gastrointestinal (GI) cancers with high plasma tumor mutational burden (pTMB): Results from a SCRUM-Japan GOZILA phase II trial. This is an ASCO Meeting ...

The Hepzato Kit is the first FDA-approved liver-directed therapy for unresectable metastatic uveal melanoma, showing consistent efficacy across diverse patient subgroups. Patients with lower tumor ...

First-line nivolumab plus ipilimumab significantly improved survival versus lenvatinib or sorafenib in patients with unresectable liver cancer. The median overall survival of 23.7 months with the ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has granted Priority Review to the ...